Braintree, Buyers Settle Generic MiraLax Suit For $17M
Drug buyer plaintiffs in a putative antitrust class action accusing Braintree Laboratories Inc. of initiating baseless patent litigation to block a generic version of the laxative MiraLax asked a Delaware federal...To view the full article, register now.
Already a subscriber? Click here to view full article